Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Surrozen, Inc. (SRZN)
USD21.72
-0.16 (-0.73%)
US NASDAQ Healthcare Biotechnology
Address
171 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Craig Parker
Website
surrozen.com
IPO
2021-01-11
CIK 1824893 ISIN US86889P2083
Also trades on
NASDAQ Capital Market · SRZN (USD)
NASDAQ Capital Market · SRZNW (USD)
New York Stock Exchange Arca · CHFW-UN (USD)
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| Rule | 2021-05-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD21.72
-0.16 (-0.73%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
131.5K
Beta
0.51
Float Shares
3.27M
Free Float %
43.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.71% | -0.94% | +2.68% | +25.25% | +152.97% | +35.66% | +325.83% | +240.78% | -79.29% | -79.78% | -79.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
21.72
Low
40.00
+84.2%
Consensus
42.00
+93.4%
Median
42.00
+93.4%
High
44.00
+102.6%
DCF (Unlevered)
11.39
-47.6%
DCF (Levered)
10.82
-50.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
44.00
+102.6%
|
| Last Quarter | 2 |
42.00
+93.4%
|
| Last Year | 2 |
42.00
+93.4%
|
| All Time | 4 |
40.25
+85.3%
|
Quality scores
Altman Z-Score
-9.01
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-67.4% Q1'26: +408.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-49.4% Q1'26: -56.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,108.1% Q1'26: -252.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,210.6% Q1'26: -209.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +11.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+155.0% Q1'26: +201.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
12.50M
est: 12.50M (+0.0%)
|
10.66M
est: 10.00M (+6.6%)
|
3.48M
est: 2.29M (+51.6%)
|
6.40M
6.01M – 7.18M
+179.1% YoY
|
869.3K
816.6K – 974.6K
-86.4% YoY
|
869.3K
816.6K – 974.6K
+0.0% YoY
|
869.3K
816.6K – 974.6K
+0.0% YoY
|
5.02M
4.71M – 5.62M
+477.0% YoY
|
| EBITDA |
-42.38M
est: 2.50M (-1,795.4%)
|
-24.10M
est: -2.00M (-1,104.9%)
|
-41.56M
est: -458.7K (-8,958.6%)
|
-1.28M
-1.44M – -1.20M
-179.1% YoY
|
-173.8K
-194.9K – -163.3K
+86.4% YoY
|
-173.8K
-194.9K – -163.3K
+0.0% YoY
|
-173.8K
-194.9K – -163.3K
+0.0% YoY
|
-1.00M
-1.12M – -942.3K
-477.0% YoY
|
| EBIT |
-44.34M
est: 2.50M (-1,873.6%)
|
-25.54M
est: -2.00M (-1,177.0%)
|
-42.09M
est: -458.7K (-9,075.7%)
|
-1.28M
-1.44M – -1.20M
-179.1% YoY
|
-173.8K
-194.9K – -163.3K
+86.4% YoY
|
-173.8K
-194.9K – -163.3K
+0.0% YoY
|
-173.8K
-194.9K – -163.3K
+0.0% YoY
|
-1.00M
-1.12M – -942.3K
-477.0% YoY
|
| Net Income |
-36.00M
est: -63.22M (+43.0%)
|
-63.56M
est: -116.12M (+45.3%)
|
-242.03M
est: -65.53M (-269.4%)
|
-96.61M
-105.83M – -87.40M
-47.4% YoY
|
-30.24M
-36.21M – -24.28M
+68.7% YoY
|
-27.67M
-35.15M – -20.19M
+8.5% YoY
|
-27.26M
-31.55M – -25.11M
+1.5% YoY
|
-29.59M
-34.26M – -27.26M
-8.6% YoY
|
| SGA |
19.83M
est: 15.00M (+32.2%)
|
15.06M
est: 19.32M (-22.0%)
|
16.20M
est: 4.43M (+265.7%)
|
12.37M
11.62M – 13.87M
+179.1% YoY
|
1.68M
1.58M – 1.88M
-86.4% YoY
|
1.68M
1.58M – 1.88M
+0.0% YoY
|
1.68M
1.58M – 1.88M
+0.0% YoY
|
9.69M
9.10M – 10.86M
+477.0% YoY
|
| EPS |
-15.55
est: -21.55 (+27.9%)
|
-21.67
est: -14.94 (-45.0%)
|
-32.37
est: -8.76 (-269.4%)
|
-13.06
-14.15 – -11.69
-49.0% YoY
|
-4.05
-4.84 – -3.25
+69.0% YoY
|
-3.42
-4.70 – -2.70
+15.6% YoY
|
-3.65
-4.22 – -3.36
-6.7% YoY
|
-3.96
-4.58 – -3.65
-8.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-64.94M
OE per share TTM
-7.59
Owner's Yield
-19.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
221.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
54
Total invested
153.25M
Insider transactions (90d)
6
Beneficial owners (>5%)
43
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kutzkey | 9.41M | 25.70% | — | 9.41M | — | 9.41M | IN | — | 2021-08-23 | ↗ |
| 2 | LP | 9.41M | 25.70% | — | 9.41M | — | 9.41M | PN | — | 2021-08-23 | ↗ |
| 3 | Consonance Capman GP LLC | 6.06M | 9.99% | — | 6.06M | — | — | HC, OO | Delaware USA | 2021-02-16 | ↗ |
| 4 | Mitchell Blutt | 6.06M | 9.99% | — | 6.06M | — | — | HC, IN | Delaware USA | 2021-02-16 | ↗ |
| 5 | III-A, | 4.99M | 13.70% | — | 4.99M | — | 4.99M | PN | — | 2021-08-23 | ↗ |
| 6 | Baker Bros. Advisors (GP) LLC | 3.33M | 9.30% | 3.33M | — | 3.33M | — | HC, OO | Delaware | 2022-02-14 | ↗ |
| 7 | Baker Bros. Advisors LP | 3.33M | 9.30% | 3.33M | — | 3.33M | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 8 | Felix J. Baker | 3.33M | 9.30% | 3.33M | — | 3.33M | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 9 | Julian C. Baker | 3.33M | 9.30% | 3.33M | — | 3.33M | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 10 | Regents of the University of California | 2.08M | 5.94% | 2.08M | — | 2.08M | — | EP | U.S. | 2022-01-27 | ↗ |
| 11 | Chidozie Ugwumba | 1.96M | 5.50% | 1.96M | — | 1.96M | — | IN | United States | 2022-05-10 | ↗ |
| 12 | BML Investment Partners, L.P. | 1.67M | 5.60% | — | 1.67M | — | 1.67M | PN | — | 2023-02-02 | ↗ |
| 13 | Consonance Capital Opportunity Fund Management LP | 1.19M | 2.04% | — | 1.19M | — | — | IA, PN | Delaware USA | 2021-02-16 | ↗ |
| 14 | Consonance Capital Management LP | 871.1K | 9.04% | — | 871.1K | — | — | IA, PN | Delaware USA | 2021-02-16 | ↗ |
| 15 | Feis Equities LLC | 687.6K | 7.14% | 687.6K | — | 687.6K | — | IV, OO | Illinois | 2021-08-05 | ↗ |
| 16 | Company, L.P. | 500.0K | 5.95% | — | 500.0K | — | — | PN | Delaware | 2020-12-08 | ↗ |
| 17 | Deerfield Mgmt, L.P. | 500.0K | 5.95% | — | 500.0K | — | — | PN | Delaware | 2020-12-08 | ↗ |
| 18 | Deerfield Partners, L.P. | 500.0K | 5.95% | — | 500.0K | — | — | PN | Delaware | 2020-12-08 | ↗ |
| 19 | James E. Flynn | 500.0K | 5.95% | — | 500.0K | — | — | IN | Delaware | 2020-12-08 | ↗ |
| 20 | Benny Soffer | 434.0K | 4.50% | — | 434.0K | — | 10.00 | IN | United States | 2020-12-03 | ↗ |
| 21 | Kevin Livingston | 434.0K | 4.50% | — | 434.0K | — | 10.00 | IN | United States | 2020-12-03 | ↗ |
| 22 | Michelle Ross | 427.8K | 12.80% | — | 377.8K | — | — | IN | Delaware | 2024-11-01 | ↗ |
| 23 | StemPoint Capital LP | 427.8K | 12.80% | — | 377.8K | — | — | IA | Delaware | 2024-11-01 | ↗ |
| 24 | StemPoint Capital Management GP LLC | 427.8K | 12.80% | — | 377.8K | — | — | CO | Delaware | 2024-11-01 | ↗ |
| 25 | Peter Kolchinsky | 323.7K | 9.99% | — | 323.7K | — | 323.7K | HC, IN | Delaware | 2024-04-15 | ↗ |
| 26 | RA Capital Healthcare Fund, L.P. | 323.7K | 9.99% | — | 323.7K | — | 323.7K | PN | Delaware | 2024-04-15 | ↗ |
| 27 | RA Capital Management, L.P. | 323.7K | 9.99% | — | 323.7K | — | 323.7K | IA, PN | Delaware | 2024-04-15 | ↗ |
| 28 | Rajeev Shah | 323.7K | 9.99% | — | 323.7K | — | 323.7K | HC, IN | Delaware | 2024-04-15 | ↗ |
| 29 | Alyeska Fund GP, LLC | 203.6K | 9.99% | — | 203.6K | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 30 | Alyeska Investment Group, L.P. | 203.6K | 9.99% | — | 203.6K | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 31 | Anand Parekh | 203.6K | 9.99% | — | 203.6K | — | — | IN | United States of America | 2024-02-14 | ↗ |
| 32 | Jon M. Plexico | 199.2K | 11.00% | — | 199.2K | — | 199.2K | HC, IN | U.S.A. | 2024-04-19 | ↗ |
| 33 | Stonepine Capital Management, LLC | 199.2K | 11.00% | — | 199.2K | — | 199.2K | IA, OO | Delaware | 2024-04-19 | ↗ |
| 34 | Stonepine Capital, L.P. | 199.2K | 11.00% | — | 199.2K | — | 199.2K | PN | Delaware | 2024-04-19 | ↗ |
| 35 | Stonepine GP, LLC | 199.2K | 11.00% | — | 199.2K | — | 199.2K | OO | Delaware | 2024-04-19 | ↗ |
| 36 | Timothy P. Lynch | 199.2K | 11.00% | — | 199.2K | — | 199.2K | HC, IN | U.S.A. | 2024-04-19 | ↗ |
| 37 | GOLDMAN SACHS & CO. LLC | 79.4K | 2.40% | — | 79.4K | — | 79.4K | BD, IA, OO | — | 2024-11-08 | ↗ |
| 38 | THE GOLDMAN SACHS GROUP, INC. | 79.4K | 2.40% | — | 79.4K | — | 79.4K | HC, CO | — | 2024-11-08 | ↗ |
| 39 | BRIDGER MANAGEMENT, LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-14 | ↗ |
| 40 | Glazer Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | State of Delaware | 2022-02-14 | ↗ |
| 41 | Paul J. Glazer | — | 0.00% | — | — | — | — | IN | United States | 2022-02-14 | ↗ |
| 42 | ROBERTO MIGNONE | — | 0.00% | — | — | — | — | IN | United States | 2022-02-14 | ↗ |
| 43 | SWIFTCURRENT PARTNERS, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
54
+19 vs prev Q
New positions
26
Closed positions
7
Increased
42
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EMPERY ASSET MANAGEMENT, LP | 104.0K +104.0K (+100.0%) | 2.35B +2.3B (+100.0%) | 1.21% +1.213 pp | 2.07% +2.072 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 2 | — | 385.2K +385.2K (+100.0%) | 1.89B +1.9B (+100.0%) | 4.49% +4.494 pp | 1.87% +1.866 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 3 | MILLENNIUM MANAGEMENT LLC | 721.3K +611.5K (+557.1%) | 16.30M +14.9M (+1,052.5%) | 8.42% +7.130 pp | 0.01% +0.006 pp | USD21.12 +7.0% | 2 qtrs — |
| 4 | VR ADVISER, LLC | 632.9K +— (+0.0%) | 14.30M +6.1M (+75.4%) | 7.38% -0.026 pp | 0.71% +0.248 pp | USD11.66 +93.8% | 4 qtrs — |
| 5 | STEMPOINT CAPITAL LP | 619.8K -93.7K (-13.1%) | 12.67M +3.5M (+37.8%) | 7.23% -1.122 pp | 2.17% +0.331 pp | USD10.32 +119.0% | 7 qtrs — |
| 6 | BRAIDWELL LP | 470.0K +330.0K (+235.7%) | 10.62M +8.8M (+488.8%) | 5.48% +3.845 pp | 0.34% +0.286 pp | USD18.53 +22.0% | 3 qtrs — |
| 7 | BOXER CAPITAL MANAGEMENT, LLC | 416.2K +416.2K (+100.0%) | 9.40M +9.4M (+100.0%) | 4.86% +4.855 pp | 2.06% +2.059 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 8 | 5AM VENTURE MANAGEMENT, LLC | 387.5K +77.5K (+25.0%) | 8.76M +4.8M (+119.2%) | 4.52% +0.892 pp | 2.75% +1.290 pp | USD13.85 +63.2% | 4 qtrs — |
| 9 | VANGUARD GROUP INC | 319.2K +52.8K (+19.8%) | 7.21M +3.8M (+110.2%) | 3.72% +0.605 pp | 0.00% +0.000 pp | USD12.00 +88.3% | 9 qtrs — |
| 10 | VIVO CAPITAL, LLC | 260.0K +— (+0.0%) | 5.88M +2.5M (+75.4%) | 3.03% -0.011 pp | 0.38% +0.110 pp | USD11.66 +93.8% | 4 qtrs — |
| 11 | WOODLINE PARTNERS LP | 230.6K +182.4K (+378.4%) | 5.21M +4.6M (+739.2%) | 2.69% +2.126 pp | 0.02% +0.017 pp | USD20.57 +9.9% | 2 qtrs — |
| 12 | NANTAHALA CAPITAL MANAGEMENT, LLC | 229.5K +— (+0.0%) | 5.19M +2.2M (+75.4%) | 2.68% -0.009 pp | 0.17% +0.069 pp | USD10.98 +105.8% | 7 qtrs — |
| 13 | BALYASNY ASSET MANAGEMENT L.P. | 190.5K +119.8K (+169.3%) | 4.31M +3.4M (+372.4%) | 2.22% +1.394 pp | 0.01% +0.004 pp | USD18.99 +19.0% | 2 qtrs — |
| 14 | ACUTA CAPITAL PARTNERS, LLC | 178.4K +— (+0.0%) | 4.03M +1.7M (+75.4%) | 2.08% -0.007 pp | 2.74% +0.362 pp | USD11.72 +92.8% | 4 qtrs — |
| 15 | SILVERARC CAPITAL MANAGEMENT, LLC | 157.3K +157.3K (+100.0%) | 3.56M +3.6M (+100.0%) | 1.84% +1.836 pp | 0.49% +0.494 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 16 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 133.2K +— (+0.0%) | 3.01M +1.3M (+75.4%) | 1.55% -0.006 pp | 0.14% +0.005 pp | USD14.35 +57.5% | 5 qtrs — |
| 17 | STONEPINE CAPITAL MANAGEMENT, LLC | 113.6K -136.5K (-54.6%) | 2.57M -655.1K (-20.3%) | 1.33% -1.603 pp | 1.87% -0.745 pp | USD11.56 +95.5% | 7 qtrs — |
| 18 | FRED ALGER MANAGEMENT, LLC | 99.6K +99.6K (+100.0%) | 2.25M +2.3M (+100.0%) | 1.16% +1.162 pp | 0.01% +0.009 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 19 | EVERSEPT PARTNERS, LP | 95.3K +18.3K (+23.8%) | 2.15M +1.2M (+117.1%) | 1.11% +0.210 pp | 0.11% +0.040 pp | USD14.75 +53.2% | 2 qtrs — |
| 20 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 88.7K +— (+0.0%) | 2.00M +861.3K (+75.4%) | 1.03% -0.004 pp | 0.00% +0.001 pp | USD13.62 +65.9% | 5 qtrs — |
| 21 | EUCLIDEAN CAPITAL LLC | 87.7K +— (+0.0%) | 1.98M +852.0K (+75.4%) | 1.02% -0.004 pp | 0.54% +0.062 pp | USD9.40 +140.4% | 9 qtrs — |
| 22 | SCHONFELD STRATEGIC ADVISORS LLC | 74.6K +5.6K (+8.1%) | 1.69M +797.6K (+89.7%) | 0.87% +0.063 pp | 0.01% +0.002 pp | USD13.62 +65.9% | 2 qtrs — |
| 23 | GEODE CAPITAL MANAGEMENT, LLC | 67.0K +12.5K (+22.9%) | 1.51M +811.7K (+115.5%) | 0.78% +0.143 pp | 0.00% +0.000 pp | USD13.62 +65.9% | 9 qtrs — |
| 24 | IKARIAN CAPITAL, LLC | 65.8K +65.8K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.77% +0.768 pp | 0.12% +0.116 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 25 | AMERIPRISE FINANCIAL INC | 65.7K +65.7K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.77% +0.766 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 26 | ARROWMARK COLORADO HOLDINGS LLC | 55.1K +— (+0.0%) | 1.25M +535.5K (+75.4%) | 0.64% -0.002 pp | 0.03% +0.014 pp | USD9.40 +140.4% | 9 qtrs — |
| 27 | 683 CAPITAL MANAGEMENT, LLC | 42.0K +42.0K (+100.0%) | 949.2K +949.2K (+100.0%) | 0.49% +0.490 pp | 0.04% +0.041 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 28 | WALLEYE CAPITAL LLC | 41.0K +41.0K (+100.0%) | 927.5K +927.5K (+100.0%) | 0.48% +0.479 pp | 0.00% +0.003 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 29 | MORGAN STANLEY | 37.0K +2.2K (+6.3%) | 835.3K +387.4K (+86.5%) | 0.43% +0.024 pp | 0.00% +0.000 pp | USD10.18 +122.0% | 9 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 29.6K +29.6K (+493,366.7%) | 669.1K +669.1K (+868,914.3%) | 0.35% +0.345 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 7 qtrs — |
| 31 | JANE STREET GROUP, LLC | 27.6K +27.6K (+100.0%) | 624.3K +624.3K (+100.0%) | 0.32% +0.322 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 32 | BLACKROCK, INC. | 26.1K +12.4K (+90.0%) | 590.3K +413.2K (+233.3%) | 0.30% +0.144 pp | 0.00% +0.000 pp | USD16.27 +38.9% | 6 qtrs — |
| 33 | GOLDMAN SACHS GROUP INC | 25.8K +25.8K (+100.0%) | 583.6K +583.6K (+100.0%) | 0.30% +0.301 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 34 | STATE STREET CORP | 24.3K +11.0K (+82.5%) | 549.8K +378.1K (+220.2%) | 0.28% +0.128 pp | 0.00% +0.000 pp | USD17.28 +30.8% | 2 qtrs — |
| 35 | LMR PARTNERS LLP | 23.6K +23.6K (+100.0%) | 532.4K +532.4K (+100.0%) | 0.27% +0.275 pp | 0.00% +0.001 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 36 | RENAISSANCE TECHNOLOGIES LLC | 22.6K +7.9K (+53.6%) | 511.3K +321.6K (+169.5%) | 0.26% +0.092 pp | 0.00% +0.001 pp | USD14.34 +57.6% | 9 qtrs — |
| 37 | PRICE T ROWE ASSOCIATES INC /MD/ | 21.7K +— (+0.0%) | 491.0K +211.0K (+75.4%) | 0.25% -0.001 pp | 0.00% +0.000 pp | USD11.98 +88.6% | 6 qtrs — |
| 38 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 18.9K +18.9K (+100.0%) | 427.6K +427.6K (+100.0%) | 0.22% +0.221 pp | 0.00% +0.005 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 39 | BOOTHBAY FUND MANAGEMENT, LLC | 18.3K +18.3K (+100.0%) | 413.7K +413.7K (+100.0%) | 0.21% +0.214 pp | 0.01% +0.006 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 40 | QUADRATURE CAPITAL LTD | 14.8K +14.8K (+100.0%) | 334.5K +334.5K (+100.0%) | 0.17% +0.173 pp | 0.00% +0.003 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 41 | CITADEL ADVISORS LLC | 14.7K +865.0 (+6.2%) | 333.1K +154.3K (+86.3%) | 0.17% +0.010 pp | 0.00% +0.000 pp | USD10.66 +112.0% | 3 qtrs — |
| 42 | OMERS ADMINISTRATION CORP | 13.7K +13.7K (+100.0%) | 309.6K +309.6K (+100.0%) | 0.16% +0.160 pp | 0.00% +0.002 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 43 | NORTHERN TRUST CORP | 13.5K +13.5K (+100.0%) | 305.8K +305.8K (+100.0%) | 0.16% +0.158 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 44 | IEQ CAPITAL, LLC | 13.5K +13.5K (+100.0%) | 304.4K +304.4K (+100.0%) | 0.16% +0.157 pp | 0.00% +0.001 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 45 | MARSHALL WACE, LLP | 10.9K +10.9K (+100.0%) | 247.2K +247.2K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 46 | ALYESKA INVESTMENT GROUP, L.P. | 10.2K +— (+0.0%) | 230.2K +99.0K (+75.4%) | 0.12% 0.000 pp | 0.00% +0.000 pp | USD9.40 +140.4% | 9 qtrs — |
| 47 | PERSISTENT ASSET PARTNERS LTD | 4.4K +4.4K (+100.0%) | 98.5K +98.5K (+100.0%) | 0.05% +0.051 pp | 0.04% +0.044 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 2.5K +2.5K (+100.0%) | 57.0K +57.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 49 | ACADIAN ASSET MANAGEMENT LLC | 1.5K +1.5K (+100.0%) | 34.0K +34.0K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 50 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 1.5K +500.0 (+50.0%) | 33.9K +21.0K (+163.1%) | 0.02% +0.006 pp | 0.00% +0.002 pp | USD16.13 +40.1% | 2 qtrs — |
| 51 | CITIGROUP INC | 1.1K +1.1K (+100.0%) | 24.0K +24.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 52 | UBS GROUP AG | 59.00 +59.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD22.59 +0.0% | 9 qtrs — |
| 53 | ROYAL BANK OF CANADA | 65.00 +65.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD22.60 +0.0% | 1 qtrs NEW |
| 54 | SAMSARA BIOCAPITAL, LLC | — -241.4K (-100.0%) | — -3.1M (-100.0%) | 0.00% -2.826 pp | 0.00% -0.406 pp | USD— | 4 qtrs SOLD |
| 55 | BARCLAYS PLC | — -25.0 (-100.0%) | — -300.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 56 | WOLVERINE ASSET MANAGEMENT LLC | — -281.0 (-100.0%) | — -3.6K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 57 | RA CAPITAL MANAGEMENT, L.P. | — -602.6K (-100.0%) | — -7.8M (-100.0%) | 0.00% -7.056 pp | 0.00% -0.096 pp | USD— | 7 qtrs SOLD |
| 58 | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | — -47.9K (-100.0%) | — -617.6K (-100.0%) | 0.00% -0.561 pp | 0.00% -0.094 pp | USD— | 5 qtrs SOLD |
| 59 | SBI SECURITIES CO., LTD. | — -2.0 (-100.0%) | — -26.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 60 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | — -52.1K (-100.0%) | — -671.7K (-100.0%) | 0.00% -0.610 pp | 0.00% -0.079 pp | USD— | 9 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 34 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.04% | 572.1K | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 279.4K | 0.20% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.60M | 0.24% |
| 4 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 171.3K | 0.30% |
| 5 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 17.4K | 0.25% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.01% | 79.8K | 0.08% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 2.9K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.01% | 4.22M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 27.6K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 6.7K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.73
Neutral
Buys
3
Sells
6
Shares acquired
22.5K
Shares disposed
30.6K
Cash buys
—
Cash sales
3.00
Net activity
-8,144
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Williams Charles O | Officer | S-Sale | D | Common Stock | 2,036 | 33.33 | 67.9K | 16,571 | D | ↗ |
| 2026-05-04 | Parker Craig C | Director / Officer | S-Sale | D | Common Stock | 4,524 | 33.33 | 150.8K | 16,553 | D | ↗ |
| 2026-05-04 | Li Yang | Officer | S-Sale | D | Common Stock | 1,584 | 33.33 | 52.8K | 17,216 | D | ↗ |
| 2026-05-01 | Williams Charles O | Officer | M-Exempt | A | Common Stock | 5,625 | 0.00 | — | 18,607 | D | ↗ |
| 2026-05-01 | Parker Craig C | Director / Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 21,077 | D | ↗ |
| 2026-05-01 | Li Yang | Officer | M-Exempt | A | Common Stock | 4,375 | 0.00 | — | 18,800 | D | ↗ |
| 2026-03-31 | Li Yang | Officer | G-Gift | D | Common Stock | 1,666 | 0.00 | — | 14,425 | D | ↗ |
| 2026-03-24 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 53,329 | 24.69 | 1.32M | 736,547 | I | ↗ |
| 2026-03-23 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 7,612 | 24.90 | 189.5K | 683,225 | I | ↗ |
| 2026-03-16 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 595 | 24.99 | 14.9K | 675,613 | I | ↗ |
| 2026-03-13 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 17,717 | 24.88 | 440.7K | 675,018 | I | ↗ |
| 2026-03-12 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 6,187 | 24.99 | 154.6K | 657,301 | I | ↗ |
| 2026-02-17 | Williams Charles O | Officer | A-Award | A | Employee Stock Option (right to buy) | 102,900 | 24.53 | 2.52M | 102,900 | D | ↗ |
| 2026-02-17 | Parker Craig C | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 242,200 | 24.53 | 5.94M | 242,200 | D | ↗ |
| 2026-02-17 | Li Yang | Officer | A-Award | A | Restricted Stock Unit | 100,950 | 0.00 | — | 100,950 | D | ↗ |
| 2026-02-12 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 547 | 23.86 | 13.1K | 651,114 | I | ↗ |
| 2026-02-11 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 8,882 | 23.58 | 209.4K | 650,567 | I | ↗ |
| 2026-02-03 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 2,178 | 21.94 | 47.8K | 641,685 | I | ↗ |
| 2026-02-02 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 365 | 21.38 | 7.8K | 639,505 | I | ↗ |
| 2026-01-30 | TCG Crossover GP II, LLC | 10% Owner | P-Purchase | A | Common Stock | 2,136 | 21.39 | 45.7K | 639,141 | I | ↗ |
| 2026-01-26 | TCG Crossover GP II, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 637,005 | I | ↗ |
| 2026-01-23 | Williams Charles O | Officer | A-Award | A | Employee Stock Option (right to buy) | 500 | 19.60 | 9.8K | 500 | D | ↗ |
| 2026-01-20 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 9,568 | 19.60 | 187.5K | 1,016,658 | I | ↗ |
| 2026-01-20 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 9,568 | 19.60 | 187.5K | 1,016,658 | I | ↗ |
| 2026-01-16 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 1,358 | 20.00 | 27.2K | 1,007,090 | I | ↗ |
| 2026-01-16 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 1,358 | 20.00 | 27.2K | 1,007,090 | I | ↗ |
| 2026-01-15 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 6,303 | 19.89 | 125.4K | 1,005,732 | I | ↗ |
| 2026-01-15 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 5,590 | 19.89 | 111.2K | 890,604 | I | ↗ |
| 2026-01-14 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 2,927 | 19.99 | 58.5K | 999,429 | I | ↗ |
| 2026-01-14 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 2,927 | 19.99 | 58.5K | 999,429 | I | ↗ |
| 2026-01-13 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 5,861 | 19.80 | 116.1K | 882,418 | I | ↗ |
| 2026-01-13 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 5,861 | 19.80 | 116.1K | 882,418 | I | ↗ |
| 2026-01-06 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 8,003 | 19.89 | 159.2K | 989,893 | I | ↗ |
| 2026-01-06 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 8,003 | 19.89 | 159.2K | 989,893 | I | ↗ |
| 2026-01-05 | Williams Charles O | Officer | S-Sale | D | Common Stock | 1,566 | 19.87 | 31.1K | 12,982 | D | ↗ |
| 2026-01-05 | Li Yang | Officer | S-Sale | D | Common Stock | 1,118 | 19.87 | 22.2K | 16,091 | D | ↗ |
| 2026-01-02 | Williams Charles O | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 14,548 | D | ↗ |
| 2026-01-02 | Li Yang | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 17,209 | D | ↗ |
| 2025-12-15 | Williams Charles O | Officer | A-Award | A | Common Stock | 1,666 | 8.11 | 13.5K | 11,048 | D | ↗ |
| 2025-12-15 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 1,553 | 8.11 | 12.6K | 8,577 | D | ↗ |
| 2025-12-15 | Li Yang | Officer | A-Award | A | Common Stock | 1,666 | 8.11 | 13.5K | 14,709 | D | ↗ |
| 2025-12-05 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 16,381 | 19.54 | 320.1K | 981,890 | I | ↗ |
| 2025-12-05 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 16,381 | 19.54 | 320.1K | 981,890 | I | ↗ |
| 2025-12-04 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 2,791 | 17.35 | 48.4K | 965,509 | I | ↗ |
| 2025-12-04 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 2,791 | 17.35 | 48.4K | 965,509 | I | ↗ |
| 2025-11-13 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 167,307 | 12.65 | 2.12M | 962,718 | I | ↗ |
| 2025-11-13 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Common Stock | 167,307 | 12.65 | 2.12M | 962,718 | I | ↗ |
| 2025-11-12 | Maleki Andrew Pedrum | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-13 | Williams Charles O | Officer | A-Award | A | Common Stock | 400 | 8.06 | 3.2K | 9,382 | D | ↗ |
| 2025-06-13 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 400 | 8.06 | 3.2K | 7,024 | D | ↗ |
| 2025-06-13 | Li Yang | Officer | A-Award | A | Common Stock | 400 | 8.06 | 3.2K | 13,043 | D | ↗ |
| 2025-05-14 | WOODHOUSE DAVID J | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | Rothenberg Mace | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | Lin Shao-Lee | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | Haak-Frendscho Mary | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | CHAI CHRISTOPHER Y | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | Berkenblit Anna | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-14 | BJERKHOLT ERIC | Director | A-Award | A | Option (right to buy) | 1,333 | 6.50 | 8.7K | 1,333 | D | ↗ |
| 2025-05-01 | Williams Charles O | Officer | A-Award | A | Option (right to buy) | 33,750 | 10.48 | 353.7K | 33,750 | D | ↗ |
| 2025-05-01 | Parker Craig C | Director / Officer | A-Award | A | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-05-01 | Li Yang | Officer | A-Award | A | Restricted Stock Unit | 8,750 | 0.00 | — | 8,750 | D | ↗ |
| 2025-03-26 | Kutzkey Tim | Director | — | — | Series E Common Warrants | 172,414 | 11.54 | 1.99M | 0 | I | ↗ |
| 2025-03-26 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Second Tranche Units (Right to Buy) | 517,241 | 11.60 | 6.00M | 517,241 | I | ↗ |
| 2025-03-24 | Williams Charles O | Officer | D-Return | D | Series A Common Stock Warrant (right to buy) | 1,474 | 16.96 | 25.0K | 0 | D | ↗ |
| 2025-03-24 | Parker Craig C | Director / Officer | A-Award | A | Series B Common Stock Warrant (right to buy) | 1,603 | 12.45 | 20.0K | 1,603 | D | ↗ |
| 2025-01-17 | Williams Charles O | Officer | A-Award | A | Option (right to buy) | 45,000 | 12.08 | 543.6K | 45,000 | D | ↗ |
| 2025-01-17 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 100,000 | 12.08 | 1.21M | 100,000 | D | ↗ |
| 2025-01-17 | Li Yang | Officer | A-Award | A | Option (right to buy) | 35,000 | 12.08 | 422.8K | 35,000 | D | ↗ |
| 2025-01-03 | Williams Charles O | Officer | S-Sale | D | Common Stock | 1,181 | 17.37 | 20.5K | 8,982 | D | ↗ |
| 2025-01-03 | Li Yang | Officer | S-Sale | D | Common Stock | 843 | 17.37 | 14.6K | 13,345 | D | ↗ |
| 2025-01-02 | Williams Charles O | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 10,163 | D | ↗ |
| 2025-01-02 | Li Yang | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 14,188 | D | ↗ |
| 2024-06-14 | Williams Charles O | Officer | A-Award | A | Common Stock | 400 | 5.67 | 2.3K | 5,863 | — | ↗ |
| 2024-06-14 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 400 | 5.67 | 2.3K | 5,824 | — | ↗ |
| 2024-06-14 | Li Yang | Officer | A-Award | A | Common Stock | 400 | 5.67 | 2.3K | 10,888 | — | ↗ |
| 2024-06-05 | WOODHOUSE DAVID J | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | Rothenberg Mace | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | Lin Shao-Lee | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | Kutzkey Tim | Director / 10% Owner | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | Haak-Frendscho Mary | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | CHAI CHRISTOPHER Y | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | Berkenblit Anna | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-06-05 | BJERKHOLT ERIC | Director | A-Award | A | Option (right to buy) | 1,333 | 11.00 | 14.7K | 1,333 | — | ↗ |
| 2024-05-01 | Williams Charles O | Officer | A-Award | A | Option (right to buy) | 27,000 | 9.89 | 267.0K | 27,000 | — | ↗ |
| 2024-05-01 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 43,000 | 9.89 | 425.3K | 43,000 | — | ↗ |
| 2024-05-01 | Li Yang | Officer | A-Award | A | Option (right to buy) | 20,000 | 9.89 | 197.8K | 20,000 | — | ↗ |
| 2024-04-24 | Williams Charles O | Officer | A-Award | A | Restricted Stock Unit | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2024-04-24 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 43,000 | 8.97 | 385.7K | 43,000 | — | ↗ |
| 2024-04-24 | Li Yang | Officer | A-Award | A | Restricted Stock Unit | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2024-04-04 | Williams Charles O | Officer | P-Purchase | A | Series B Common Stock Warrant (right to buy) | 1,603 | 15.71 | 25.2K | 1,603 | — | ↗ |
| 2024-04-04 | Parker Craig C | Director / Officer | P-Purchase | A | Series C Common Stock Warrant (right to buy) | 5,712 | 16.00 | 91.4K | 5,712 | — | ↗ |
| 2024-04-04 | Kutzkey Tim | Director / 10% Owner | P-Purchase | A | Common Stock | 102,651 | 15.50 | 1.59M | 332,885 | — | ↗ |
| 2024-04-04 | COLUMN GROUP III GP, LP | 10% Owner | P-Purchase | A | Series C Common Warrants | 397,773 | 16.00 | 6.36M | 397,773 | — | ↗ |
| 2024-01-29 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 33 | 7.89 | 260.37 | 33 | — | ↗ |
| 2023-12-15 | Williams Charles O | Officer | A-Award | A | Common Stock | 2,085 | 5.67 | 11.8K | 2,085 | — | ↗ |
| 2023-12-15 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 2,046 | 5.67 | 11.6K | 2,046 | — | ↗ |
| 2023-12-15 | Li Yang | Officer | A-Award | A | Common Stock | 2,085 | 5.67 | 11.8K | 2,085 | — | ↗ |
| 2023-08-17 | Li Yang | Officer | — | D | Common Stock | 0 | 0.00 | — | 121,524 | — | ↗ |
| 2023-06-15 | Yeh Wen-Chen | Officer | A-Award | A | Common Stock | 17,638 | 0.38 | 6.7K | 27,216 | — | ↗ |
| 2023-06-15 | Williams Charles O | Officer | A-Award | A | Common Stock | 25,000 | 0.38 | 9.5K | 34,578 | — | ↗ |
| 2023-06-15 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.38 | 9.5K | 34,578 | — | ↗ |
| 2023-05-18 | WOODHOUSE DAVID J | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | Rothenberg Mace | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | Lin Shao-Lee | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | Kutzkey Tim | Director / 10% Owner | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | Haak-Frendscho Mary | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | CHAI CHRISTOPHER Y | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | Berkenblit Anna | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-18 | BJERKHOLT ERIC | Director | A-Award | A | Option (right to buy) | 20,000 | 0.56 | 11.2K | 20,000 | — | ↗ |
| 2023-05-05 | BJERKHOLT ERIC | Director | — | D | Option (right to buy) | 40,000 | 0.58 | 23.4K | 0 | — | ↗ |
| 2023-03-01 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 405,000 | 1.13 | 457.7K | 405,000 | — | ↗ |
| 2023-02-01 | Yeh Wen-Chen | Officer | A-Award | A | Option (right to buy) | 125,000 | 0.70 | 87.5K | 125,000 | — | ↗ |
| 2023-02-01 | Williams Charles O | Officer | A-Award | A | Option (right to buy) | 125,000 | 0.70 | 87.5K | 125,000 | — | ↗ |
| 2023-02-01 | Li Yang | Officer | — | D | Option (right to buy) | 80,000 | 0.70 | 56.0K | 0 | — | ↗ |
| 2022-12-15 | Yeh Wen-Chen | Director / Officer | A-Award | A | Common Stock | 9,578 | 0.41 | 3.9K | 229,138 | — | ↗ |
| 2022-12-15 | Williams Charles O | Director / Officer | A-Award | A | Common Stock | 9,578 | 0.41 | 3.9K | 9,578 | — | ↗ |
| 2022-12-15 | Vanhove Geertrui | Director / Officer | A-Award | A | Common Stock | 9,578 | 0.41 | 3.9K | 32,412 | — | ↗ |
| 2022-12-15 | Parker Craig C | Director / Officer | A-Award | A | Common Stock | 9,578 | 0.41 | 3.9K | 9,578 | — | ↗ |
| 2022-12-14 | BLUTT MITCHELL J MD | Director | S-Sale | D | Warrants (right to buy) | 144,666 | 0.00 | — | 0 | — | ↗ |
| 2022-10-12 | Li Yang | Officer | — | D | Option (right to buy) | 500 | 2.03 | 1.0K | 0 | — | ↗ |
| 2022-10-10 | Yeh Wen-Chen | Director / Officer | A-Award | A | Option (right to buy) | 29,567 | 0.00 | — | 29,567 | — | ↗ |
| 2022-10-10 | Williams Charles O | Director / Officer | A-Award | A | Option (right to buy) | 12,164 | 0.00 | — | 12,164 | — | ↗ |
| 2022-10-10 | Vanhove Geertrui | Director / Officer | D-Return | D | Option (right to buy) | 1,760 | 0.00 | — | 0 | — | ↗ |
| 2022-10-10 | Parker Craig C | Director / Officer | A-Award | A | Option (right to buy) | 315,310 | 0.00 | — | 315,310 | — | ↗ |
| 2022-07-01 | Yeh Wen-Chen | Director / Officer | A-Award | A | Option (right to buy) | 500 | 0.00 | — | 500 | — | ↗ |
| 2022-06-07 | WOODHOUSE DAVID J | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | Rothenberg Mace | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | Lin Shao-Lee | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | Kutzkey Tim | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | Haak-Frendscho Mary | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | CHAI CHRISTOPHER Y | Director | A-Award | A | Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-07 | Berkenblit Anna | Director | A-Award | A | Option (right to buy) | 20,000 | 2.79 | 55.8K | 20,000 | — | ↗ |
| 2022-03-01 | Yeh Wen-Chen | Director / Officer | A-Award | A | Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-01 | Williams Charles O | Director / Officer | A-Award | A | Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-01 | Vanhove Geertrui | Director / Officer | A-Award | A | Option Grant (right to buy) | 125,000 | 3.11 | 388.8K | 125,000 | — | ↗ |
| 2022-03-01 | Parker Craig C | Director / Officer | A-Award | A | Stock Option (right to buy) | 370,000 | 0.00 | — | 370,000 | — | ↗ |
| 2022-02-01 | Li Yang | Officer | — | D | Option (right to buy) | 100,000 | 3.11 | 311.0K | 0 | — | ↗ |
| 2021-08-12 | Williams Charles O | Officer | A-Award | A | Employee Stock Option (right to buy) | 14,597 | 0.00 | — | 14,597 | — | ↗ |
| 2021-08-12 | Vanhove Geertrui | Officer | A-Award | A | Employee Stock Option (right to buy) | 36,647 | 0.00 | — | 36,647 | — | ↗ |
| 2021-08-12 | Parker Craig C | Officer | A-Award | A | Stock Option (right to buy) | 183,335 | 0.00 | — | 183,335 | — | ↗ |
| 2021-08-11 | Yeh Wen-Chen | Officer | — | D | Employee Stock Option (right to buy) | 35,129 | 10.76 | 378.0K | — | — | ↗ |
| 2021-08-11 | Williams Charles O | Officer | — | D | Employee Stock Option (right to buy) | 175,648 | 5.12 | 899.3K | — | — | ↗ |
| 2021-08-11 | WOODHOUSE DAVID J | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-08-11 | Vanhove Geertrui | Officer | — | D | Common Stock | 0 | 0.00 | — | 22,834 | — | ↗ |
| 2021-08-11 | Soffer Gad | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-11 | Soffer Benny | Director | A-Award | A | Common Stock | 1,451,000 | 0.00 | — | 1,885,000 | — | ↗ |
| 2021-08-11 | Santel Donald J | Director | D-Return | D | Class B Ordinary Shares | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2021-08-11 | Rothenberg Mace | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-08-11 | Parker Craig C | Officer | — | D | Employee Stock Option (right to buy) | 351,297 | 10.76 | 3.78M | — | — | ↗ |
| 2021-08-11 | Livingston Kevin Harold | Director | A-Award | A | Common Stock | 1,451,000 | 0.00 | — | 1,885,000 | — | ↗ |
| 2021-08-11 | Lin Shao-Lee | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-08-11 | Kutzkey Tim | Director | — | I | Common Stock Warrant (right to buy) | 88,394 | 11.50 | 1.02M | — | — | ↗ |
| 2021-08-11 | Jarrett Jennifer | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2021-08-11 | House Joshua Cory | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-11 | Haqq Christopher | Director | D-Return | D | Class B Ordinary Shares | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2021-08-11 | Haak-Frendscho Mary | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-08-11 | Consonance Life Sciences | Director | D-Return | D | Warrants | 144,667 | 0.00 | — | 0 | — | ↗ |
| 2021-08-11 | Consonance Capman GP, LLC | Director | A-Award | A | Common Stock | 1,248,750 | 0.00 | — | 1,748,750 | — | ↗ |
| 2021-08-11 | COLUMN GROUP III, LP | Director | — | I | Common Stock Warrant (right to buy) | 88,394 | 11.50 | 1.02M | — | — | ↗ |
| 2021-08-11 | CHAI CHRISTOPHER Y | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-08-11 | Berkenblit Anna | Director | — | D | Common Stock | 0 | 0.00 | — | 35,129 | — | ↗ |
| 2021-02-01 | Li Yang | Officer | — | D | Option (right to buy) | 22,835 | 2.16 | 49.3K | 0 | — | ↗ |
| 2020-12-01 | Soffer Benny | Director | A-Award | A | Warrant | 8,000 | 0.00 | — | 144,667 | — | ↗ |
| 2020-12-01 | Livingston Kevin Harold | Officer | A-Award | A | Class A Ordinary Shares | 24,000 | 0.00 | — | 434,000 | — | ↗ |
| 2020-12-01 | Consonance Life Sciences | Director | A-Award | A | Class A Ordinary Shares | 24,000 | 0.00 | — | 434,000 | — | ↗ |
| 2020-12-01 | BLUTT MITCHELL J MD | Director | P-Purchase | A | Warrant | 8,000 | 0.00 | — | 144,667 | — | ↗ |
| 2020-11-23 | Soffer Benny | Director | A-Award | A | Warrant | 136,667 | 0.00 | — | 136,667 | — | ↗ |
| 2020-11-23 | Livingston Kevin Harold | Officer | A-Award | A | Class A Ordinary Shares | 410,000 | 0.00 | — | 410,000 | — | ↗ |
| 2020-11-23 | Consonance Life Sciences | Director | A-Award | A | Class A Ordinary Shares | 410,000 | 0.00 | — | 410,000 | — | ↗ |
| 2020-11-23 | Consonance Capman GP, LLC | Director | P-Purchase | A | Class A Ordinary Shares | 128,900 | 0.00 | — | 128,900 | — | ↗ |
| 2020-11-23 | BLUTT MITCHELL J MD | Director | P-Purchase | A | Warrant | 136,667 | 0.00 | — | 136,667 | — | ↗ |
| 2020-11-18 | Soffer Gad | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-18 | Soffer Benny | Director | — | I | Class B Ordinary Shares | 2,300,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | Santel Donald J | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | Livingston Kevin Harold | Officer | — | I | Class B Ordinary Shares | 2,300,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | Jarrett Jennifer | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | House Joshua Cory | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-18 | Haqq Christopher | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | Consonance Life Sciences | Director | — | D | Class B Ordinary Shares | 2,300,000 | 0.00 | — | — | — | ↗ |
| 2020-11-18 | Consonance Capital Management LP | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-18 | BLUTT MITCHELL J MD | Director | — | I | Class B Ordinary Shares | 2,300,000 | 0.00 | — | — | — | ↗ |
| 2020-11-10 | Soffer Benny | Director | D-Return | D | Class B Ordinary Shares | 575,000 | 0.00 | — | 2,300,000 | — | ↗ |
| 2020-11-10 | Livingston Kevin Harold | Officer | D-Return | D | Class B Ordinary Shares | 575,000 | 0.00 | — | 2,300,000 | — | ↗ |
| 2020-11-10 | Consonance Life Sciences | Director | D-Return | D | Class B Ordinary Shares | 575,000 | 0.00 | — | 2,300,000 | — | ↗ |
| 2020-11-10 | BLUTT MITCHELL J MD | Director | D-Return | D | Class B Ordinary Shares | 575,000 | 0.00 | — | 2,300,000 | — | ↗ |
| 2020-10-08 | Soffer Benny | Director | D-Return | D | Class B Ordinary Shares | 718,750 | 0.00 | — | 2,875,000 | — | ↗ |
| 2020-10-08 | Livingston Kevin Harold | Officer | D-Return | D | Class B Ordinary Shares | 718,750 | 0.00 | — | 2,875,000 | — | ↗ |
| 2020-10-08 | Consonance Life Sciences | Director | D-Return | D | Class B Ordinary Shares | 718,750 | 0.00 | — | 2,875,000 | — | ↗ |
| 2020-10-08 | BLUTT MITCHELL J MD | Director | D-Return | D | Class B Ordinary Shares | 718,750 | 0.00 | — | 2,875,000 | — | ↗ |
| 2020-09-04 | Soffer Benny | Director | A-Award | A | Class B Ordinary Shares | 3,593,750 | 0.01 | 25.2K | 3,593,750 | — | ↗ |
| 2020-09-04 | Livingston Kevin Harold | Officer | A-Award | A | Class B Ordinary Shares | 3,593,750 | 0.01 | 25.2K | 3,593,750 | — | ↗ |
| 2020-09-04 | Consonance Life Sciences | Director | A-Award | A | Class B Ordinary Shares | 3,593,750 | 0.01 | 25.2K | 3,593,750 | — | ↗ |
| 2020-09-04 | BLUTT MITCHELL J MD | Director | A-Award | A | Class B Ordinary Shares | 3,593,750 | 0.01 | 25.2K | 3,593,750 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.0K
Shares Outstanding
7.48M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Craig Parker President and Chief Executive Officer | 630.0K | — | 262.0K | 1.58M | 346.5K | — | 2.82M | 65.36% | ↗ |
| 2 | 2025 | Charles Williams Chief Operating Officer and Corporate Secretary | 485.0K | 7.8K | 117.9K | 711.2K | 194.0K | 3.0K | 1.52M | 54.59% | ↗ |
| 3 | 2025 | Yang Li, Ph.D. Executive Vice President, Research | 456.5K | — | 91.7K | 553.2K | 182.6K | 3.0K | 1.29M | 50.11% | ↗ |
| 4 | 2024 | Craig Parker President and Chief Executive Officer | 605.0K | — | — | 627.7K | 287.4K | — | 1.52M | 41.29% | ↗ |
| 5 | 2024 | Charles Williams Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 463.3K | — | 62.8K | 296.9K | 181.4K | 3.0K | 1.01M | 35.71% | ↗ |
| 6 | 2024 | Charles Williams Chief Operating Officer and Corporate Secretary | 463.3K | — | 62.8K | 296.9K | 181.4K | 3.0K | 1.01M | 35.71% | ↗ |
| 7 | 2024 | Yang Li, Ph.D. Executive Vice President, Research | 415.0K | — | 44.9K | 222.5K | 161.9K | 3.0K | 847.2K | 31.56% | ↗ |
| 8 | 2023 | Craig Parker President and Chief Executive Officer | 580.3K | — | — | 339.9K | 245.0K | — | 1.17M | 29.17% | ↗ |
| 9 | 2023 | Wen-Chen Yeh, M.D., Ph.D. Former Chief Scientific Officer | 262.4K | — | — | 64.5K | — | 389.4K | 716.3K | 9.00% | ↗ |
| 10 | 2023 | Charles Williams Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 444.5K | — | — | 64.5K | 163.6K | 3.0K | 675.5K | 9.55% | ↗ |
| 11 | 2023 | Yang Li, Ph.D. Executive Vice President, Research | 389.3K | — | — | 41.3K | 143.2K | 3.0K | 576.7K | 7.16% | ↗ |
| 12 | 2022 | Craig Parker President and Chief Executive Officer | 558.0K | — | — | 1.14M | 195.3K | — | 1.90M | 60.26% | ↗ |
| 13 | 2022 | Charles Williams Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 423.3K | — | — | 340.7K | 139.7K | 500.00 | 904.2K | 37.68% | ↗ |
| 14 | 2022 | Charles Williams Chief Financial Officer | 423.3K | — | — | 340.7K | 139.7K | 500.00 | 904.2K | 37.68% | ↗ |
| 15 | 2022 | Wen-Chen Yeh, M.D., Ph.D. Former Chief Scientific Officer | 428.4K | — | — | 292.9K | 145.7K | 500.00 | 867.5K | 33.77% | ↗ |
| 16 | 2022 | Wen-Chen Yeh, M.D., Ph.D. Chief Scientific Officer | 428.4K | — | — | 292.9K | 145.7K | 500.00 | 867.5K | 33.77% | ↗ |
| 17 | 2022 | Yang Li, Ph.D. Executive Vice President, Research | 360.5K | — | — | 191.6K | 110.4K | 500.00 | 663.0K | 28.89% | ↗ |
| 18 | 2021 | Craig Parker President and Chief Executive Officer | 495.8K | — | — | 3.47M | 246.2K | — | 4.21M | 82.39% | ↗ |
| 19 | 2021 | Wen-Chen Yeh, M.D., Ph.D. Chief Scientific Officer | 376.3K | — | — | 216.0K | 151.2K | 500.00 | 744.1K | 29.04% | ↗ |
| 20 | 2021 | Charles Williams Chief Financial Officer | 374.4K | — | — | 104.3K | 156.0K | 500.00 | 635.2K | 16.42% | ↗ |
| 21 | 2020 | Charles Williams Chief Financial Officer | 30.5K | 40.0K | — | 510.8K | — | — | 581.3K | 87.87% | ↗ |
| 22 | 2020 | Craig Parker President and Chief Executive Officer | 441.0K | — | — | — | 112.5K | — | 553.5K | 0.00% | ↗ |
| 23 | 2020 | Wen-Chen Yeh, M.D., Ph.D. Chief Scientific Officer | 358.0K | — | — | 57.1K | 82.0K | 500.00 | 497.6K | 11.47% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Craig C. Parker | Chief Executive Officer, President & Director | 976.5K | male |
| Charles Williams | Chief Operating Officer & Corporate Secretary | 689.8K | male |
| Li Yang | Executive Vice President of Research | 642.1K | — |
| Yang Li | Executive Vice President of Research | 642.1K | — |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | — | — |
| Michael Lauw | Senior Vice President of Development Operations | — | male |
| Roeland Nusse | Co-Founder & Member of Scientific Advisory Board | — | — |
| Esther Jhun | Controller | — | — |
| Calvin Kuo | Co-Founder & Member of Scientific Advisory Board | — | — |
| Daniel L. Chao | Vice President and Head of Clinical Development | — | male |
| Andrew Maleki | Chief Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRZN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
